SCHEMBL17294010

SCHEMBL17294010

CC(C)(C)OC(=O)N1CCN(C(=O)CCCCCNC(=O)OCc2ccccc2)CCN(C(=O)OC(C)(C)C)CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 2/20 0.59
PREP P48147 2/20 0.55
HTT P42858 1/20 0.51
KEAP1 Q14145 3/20 0.51
NFE2L2 Q16236 3/20 0.51
NR2F2 P24468 1/20 0.50
RAB9A P51151 1/20 0.50
ABCB1 P08183 1/20 0.49
MAPT P10636 1/20 0.49
TGM2 P21980 1/20 0.49
ITGB3 P05106 1/20 0.49
ITGA2B P08514 1/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
DPP8 Q6V1X1 1/20 0.48
DPP7 Q9UHL4 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18165184 0.96 SIGMAR1 (0.64) SIGMAR1PREPHTTKEAP1NFE2L2
SCHEMBL17294006 0.96 SIGMAR1 (0.64) SIGMAR1PREPHTTKEAP1NFE2L2
SCHEMBL11266194 0.89 HTT (0.63) SIGMAR1PREPHTTKEAP1NFE2L2
SCHEMBL18751224 0.88 SIGMAR1 (0.59) SIGMAR1KEAP1NFE2L2ABCB1MAPT
SCHEMBL30785030 0.88 SIGMAR1 (0.70) SIGMAR1PREPHTTRAB9AMAPT
SCHEMBL6220780 0.85 SIGMAR1 (0.61) SIGMAR1HTTKEAP1NFE2L2ABCB1
SCHEMBL30750666 0.85 SIGMAR1 (0.61) SIGMAR1HTTKEAP1NFE2L2ABCB1
SCHEMBL18751212 0.85 SIGMAR1 (0.60) SIGMAR1PREPHTTMEN1KMT2A
SCHEMBL3049200 0.85 SIGMAR1 (0.60) SIGMAR1PREPHTTMEN1KMT2A
SCHEMBL29889007 0.83 SIGMAR1 (0.56) SIGMAR1KEAP1NFE2L2MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10077284-B2 UBA5 inhibitors THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2018-09-18 US disclosed
US-20170107247-A1 UBA5 INHIBITORS THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2017-04-20 US disclosed
US-20170107247-A1 UBA5 INHIBITORS THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2017-04-20 US disclosed
US-20170107247-A1 UBA5 INHIBITORS THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2017-04-20 US disclosed
WO-2015179955-A1 UBA5 INHIBITORS THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2015-12-03 WO disclosed
WO-2015179955-A1 UBA5 INHIBITORS THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2015-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10077284-B2 UBA5 inhibitors UBQLN2, UBTF, UBQLN1 SIGMAR1 2617/4885PREP 3749/4885HTT 1483/4885
US-20170107247-A1 UBA5 INHIBITORS UBQLN2, UBTF, UBQLN1 SIGMAR1 2617/4885PREP 3749/4885HTT 1483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.